Click on headlines below to download research

Momentum continues across key franchises
Laboratorios Farmacéuticos ROVI | 11/11/2020

Reported 9M20 numbers highlight continual strength in sales across key franchises and ongoing margin expansion. ROVI reported operating revenue of €302.1m…

Top-line growth, significant margin expansion
Laboratorios Farmacéuticos ROVI | 29/07/2020

Laboratorios Farmacéuticos ROVI reported H120 operating revenue of €191.1m (+8% y-o-y), driven by strong growth in heparins (+23% to €104.0m)…

COVID-19 stockpiling positive impact
Laboratorios Farmacéuticos ROVI | 18/05/2020

Laboratorios Farmacéuticos ROVI (ROVI) reported Q120 operating revenue of €101.0m (+23% y-o-y), driven by strong growth both in the speciality…

Executive interview
Executive interview - Laboratorios Farmacéuticos ROVI | 06/04/2020

ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic…

Investing for future growth
Laboratorios Farmacéuticos ROVI | 28/02/2020

Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26%…

Multiple growth drivers lie ahead
Laboratorios Farmacéuticos ROVI | 04/12/2019

Following Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent investor day, we have reviewed our near-term forecasts. Specifically, we…

Robust growth across key franchises
Laboratorios Farmacéuticos ROVI | 08/11/2019

Laboratorios Farmacéuticos ROVI (ROVI) has reported operating revenue of €270.8m (+24% y-o-y) for the first nine months of FY19 (9M19), driven…

Outperforming the market
Laboratorios Farmaceuticos ROVI | 01/08/2019

Interim results highlight the momentum at Laboratorios Farmacéuticos ROVI, as both H119 operating revenue (21% y-o-y to €177.5m) and EBITDA…

Becat roll-out benefits top-line growth
Laboratorios Farmaceuticos ROVI | 10/05/2019

Laboratorios Farmacéuticos ROVI (ROVI) reported Q119 operating revenue of €82.2m (+8% y-o-y), driven by strong growth in the speciality pharmaceutical…